FAAH抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01346(FAAH Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P01346(FAAH Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The fatty acid amide hydrolase (FAAH) antibody is a critical tool in studying FAAH, an enzyme responsible for metabolizing endocannabinoids like anandamide. FAAH regulates signaling pathways involved in pain, mood, and inflammation by breaking down bioactive lipid mediators. Researchers developed FAAH antibodies to detect, quantify, and localize FAAH expression in tissues, enabling insights into its physiological and pathological roles. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and ELISA to investigate FAAH distribution in the central nervous system, immune cells, and peripheral tissues.

FAAH has therapeutic relevance due to its association with neuropsychiatric disorders, chronic pain, and metabolic diseases. Antibodies aid in validating FAAH as a drug target, particularly for inhibitors designed to elevate endocannabinoid levels. Specificity is ensured through epitope mapping, often targeting unique regions of FAAH’s catalytic domain. Cross-reactivity studies confirm recognition across species (e.g., human, rodent), supporting translational research. Recent applications include studying FAAH in neurodegenerative diseases, cancer, and gut-brain axis modulation. However, challenges remain in standardizing antibody performance across experimental models. Overall, FAAH antibodies remain indispensable for unraveling the enzyme’s complex roles and advancing therapeutic strategies targeting the endocannabinoid system.